StockData

Drugs Made In America Acquisition Corp. (DMAA) company profile

DMAANasdaqBlank ChecksFiscal year ends December 31Also trades as DMAAR, DMAAU
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.90+0.00 (0.00%)

Close on Nov 13, 2026Market cap $264.62MP/E –Yield –

About Drugs Made In America Acquisition

Blank Checks, SIC 6770

Drugs Made In America Acquisition Corp. is a blank check shell company formed to complete a merger, share exchange, asset acquisition, reorganization, or similar corporate transaction with one or more operating businesses. The company does not market commercial products, provide commercial services, or generate operational revenue. It currently maintains no distinct business operating segments and serves no direct commercial customers. Instead, the firm focuses its acquisition efforts on enterprises operating in artificial intelligence, pharmaceuticals, or other innovation-oriented industries that require developmental support.

The company is incorporated in the Cayman Islands and maintains its principal executive offices in New York, New York. As a shell entity without active commercial operations, it owns no retail stores, production plants, or regional physical facilities. Its business search primarily targets prospective operating entities located within the United States.

Summary of the business section of Drugs Made In America Acquisition's latest annual report, written by StockData.

Company profile

Company

Legal name
Drugs Made In America Acquisition Corp.
Headquarters
New York, NY
Address
420 Lexington Avenue, Suite 1402 10170
Phone
(646) 726-7074
Employees
10, Dec 31, 2024
Industry
Blank Checks
Fiscal year ends
December 31
Auditor
MaloneBailey, LLP, Houston, Texas

Stock & identifiers

Ticker
DMAA
Other tickers
DMAAR, DMAAU
Exchange
Nasdaq
IPO date
Jan 29, 2025
Shares outstanding
24M, Aug 14, 2026
Public float
$234.60M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
2028614
CUSIP
G2847J104
FIGI
BBG01RQ5FQV1
Share class FIGI
BBG01RQ5FRS3
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Lynn StockwellCEO and Exe. Chair of Board, Director4,188,780
Glenn C. WormanCFO100,000
Catherine DoDirector100,000
Myron W. ShulganDirector100,000
Sridhar G. PrasadDirector100,000

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Jan 29, 2025
Offer price
$10.00
Securities offered
20,000,000
Gross proceeds
$200.00M
First trading day
Jan 28, 2025
First-day close
$10.000.0%
Lock-up ends (est.)
Jul 27, 2025

“Each unit has an offering price of $10.00 and consists of one ordinary share and one right to receive one -eighth (1/8) of an ordinary share upon the consummation of an initial business combination, as described in more detail below, which we refer to throughout this prospectus as the “public rights”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?